SUPPLEMENTARY DATA

Supplementary Figure 1. Insulin-stimulated glycogen synthesis in myotubes expressing GFP or ATGL in absence (-) or presence (+) of 10 μM myriocin (serine palmitoyl-CoA transferase I inhibitor). Glycogen synthesis was expressed as the delta change between glycogen synthesis under insulin stimulation and glycogen synthesis at baseline. $^{**}p<0.01$ versus GFP (n=4).



SUPPLEMENTARY DATA

Supplementary Figure 2. (A) Inset is showing a representative blot of HSL and the loading control GAPDH in control myotubes (GFP) and myotubes overexpressing HSL; Determination of (B) DAG, and (C) ceramide content in control myotubes (GFP) and myotubes overexpressing HSL (n=6). (D) Insulin-stimulated glycogen synthesis in myotubes expressing GFP and HSL (n=4). Glycogen synthesis was expressed as the delta change between glycogen synthesis under insulin stimulation and glycogen synthesis at baseline.



SUPPLEMENTARY DATA

Supplementary Figure 3. Quantitative bar graph of insulin-stimulated Ser473 Akt phosphorylation in myotubes overexpressing ATGL alone or in combination with BAY 1 M treatment (n=3); insulin-stimulated Akt phosphorylation was calculated as the delta change between basal and insulin stimulation for each condition; $^{*}p<0.05$, $^{**}p<0.01$ versus GFP.